Beyond these mechanisms, alternative signaling pathways, including the NRF2 and Hippo-YAP/TAZ pathways, have emerged as potential therapeutic targets influencing ferroptosis susceptibility in CSCs.189, 190, 191, 192 The use of ferroptosis inducers has yielded promising results in managing various cancer types, including breast cancer,193,194 ovarian cancer,195,196 and other malignancies.197. Here, NFE2L2 is linked to breast cancer.